NDATOPICALDRESSING
Approved
Nov 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SILDAFLO (silver sulfadiazine) by Inpharmus is clinical pharmacology silver sulfadiazine has broad antimicrobial activity. First approved in 1989.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SILDAFLO (silver sulfadiazine) is a topical antimicrobial cream indicated for burn wound management and prevention of bacterial infection. It acts bactericidally on the cell wall of gram-positive and gram-negative bacteria as well as yeast, with a mechanism distinct from silver nitrate or sodium sulfadiazine alone. The product is used as a topical dressing for acute and chronic wound care.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling transition from brand protection to post-LOE lifecycle management with likely team consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below. Sufficient data have been obtained to demonstrate that silver…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on SILDAFLO at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.